By Simon Hradecky, created November 01, 2018 14:50:16One of the most important questions when it comes to dementia and dementia-related conditions like CTE is whether or not a drug will be the best treatment option for those with the condition.
Drug manufacturers have developed drugs that have shown promise, but they have been plagued by some of the side effects of older patients.
Some researchers have even suggested that there may be a lack of data to support the safety and efficacy of these medications.
This year, a team of researchers from the University of Queensland in Australia looked at the efficacy and safety of a group of compounds in a drug called claudication therapy medication.
Claudication is a treatment for CTE that involves taking a drug known as a selective serotonin reuptake inhibitor (SSRI) and then using a combination of claudications and antidepressants to block the reuptakes of the brain’s neurotransmitters serotonin and norepinephrine.
Clausewitz, a professor of neurology and pharmacology at the University, said claudicate had a high level of safety and effectiveness, with more than one trial showing its effectiveness to be at least 80 per cent.
“This compound, claudicated, has shown the strongest safety and the strongest efficacy to date, and I think this is an exciting result,” he said.
“Claudicated is the strongest candidate currently available for the treatment of CTE.”
It is an important step forward in understanding how to treat this condition and it is important to understand what other compounds are available for patients with CTE, because we need to understand the risk of adverse effects, the benefits of clung, and if there are other options available.
“Professor Clauss said he hoped the study would inspire further research into claudicating and the potential of other compounds for treating CTE in the future.”
I think that we are in a very interesting period right now,” he explained.”
We are in an era where there is a lot of exciting new research coming out, and this will have an impact on what we do in the clinic, what we are going to do in research and what we will do as a profession.
“If you have a compound that is effective, you need to be aware of it, and it needs to be tested in the clinical trial and in the trials that are currently in progress, and there will be a very good public health and ethical case for it.”
The future is bright for claudicates and the rest of the therapies for treating cognitive impairment.
“Topics:dementia,drug-use,medical-research,cetacean-science,sciences,research,medical,health,sciencedirect,australia,queenslandFirst posted November 01, 2019 15:20:20Contact James FarrarMore stories from Queensland